• Profile
Close

A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults

Headache: The Journal of Head and Face Pain Oct 27, 2019

Sakai F, Takeshima T, Tatsuoka Y, et al. - Researchers undertook a phase 2, double-blind, placebo-controlled study determining the efficacy and safety of erenumab for the prevention of episodic migraine in Japanese patients. They administered placebo or erenumab 28, 70, or 140 mg subcutaneously once per month for 6 months to 475 patients. They observed greater decreases in monthly migraine days for erenumab vs placebo. As per outcomes, monthly subcutaneous injections of erenumab 70 mg exhibited statistically significant and numerically maximal efficacy with a favorable safety profile. This implies that erenumab is a potential new therapy for migraine prevention in Japan.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay